BIOMAT Database Logo BIOMAT Database Logo

Promyelocytic Blastic Crisis in Chronic Myeloid Leukemia During Imatinib Treatment. 2015

Federico Angriman, and Maria Nelly Gutierrez Acevedo, and Maria Sol Rossi, and Alberto Daniel Gimenez Conca, and Victoria Otero, and Jorge Alberto Arbelbide, and Hernán Michelángelo
Buenos Aires University School of Medicine, Hospital Italiano de Buenos Aires, Department of Internal Medicine, Buenos Aires, Argentina E-mail: federico.angriman@hospitalitaliano.org.ar Phone: +54-11-49590200 Ext: 4419.

UI MeSH Term Description Entries
D001752 Blast Crisis An advanced phase of chronic myelogenous leukemia, characterized by a rapid increase in the proportion of immature white blood cells (blasts) in the blood and bone marrow to greater than 30%. Blast Phase,Blast Crises,Blast Phases,Crises, Blast,Crisis, Blast,Phase, Blast,Phases, Blast
D001853 Bone Marrow The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. Marrow,Red Marrow,Yellow Marrow,Marrow, Bone,Marrow, Red,Marrow, Yellow
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068877 Imatinib Mesylate A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors. Alpha-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-tolu-p-toluidide,CGP 57148,CGP-57148,CGP57148B,Gleevec,Glivec,Imatinib,Imatinib Methanesulfonate,ST 1571,ST1571,STI 571,STI-571,STI571,CGP57148,Mesylate, Imatinib,Methanesulfonate, Imatinib
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D015464 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS. Granulocytic Leukemia, Chronic,Leukemia, Granulocytic, Chronic,Leukemia, Myelocytic, Chronic,Leukemia, Myelogenous, Chronic,Leukemia, Myeloid, Chronic,Myelocytic Leukemia, Chronic,Myelogenous Leukemia, Chronic,Myeloid Leukemia, Chronic,Leukemia, Chronic Myelogenous,Leukemia, Chronic Myeloid,Leukemia, Myelogenous, Ph1 Positive,Leukemia, Myelogenous, Ph1-Positive,Leukemia, Myeloid, Ph1 Positive,Leukemia, Myeloid, Ph1-Positive,Leukemia, Myeloid, Philadelphia Positive,Leukemia, Myeloid, Philadelphia-Positive,Myelogenous Leukemia, Ph1-Positive,Myeloid Leukemia, Ph1-Positive,Myeloid Leukemia, Philadelphia-Positive,Chronic Granulocytic Leukemia,Chronic Granulocytic Leukemias,Chronic Myelocytic Leukemia,Chronic Myelocytic Leukemias,Chronic Myelogenous Leukemia,Chronic Myelogenous Leukemias,Chronic Myeloid Leukemia,Chronic Myeloid Leukemias,Granulocytic Leukemias, Chronic,Leukemia, Chronic Granulocytic,Leukemia, Chronic Myelocytic,Leukemia, Ph1-Positive Myelogenous,Leukemia, Ph1-Positive Myeloid,Leukemia, Philadelphia-Positive Myeloid,Leukemias, Chronic Granulocytic,Leukemias, Chronic Myelocytic,Leukemias, Chronic Myelogenous,Leukemias, Chronic Myeloid,Leukemias, Ph1-Positive Myelogenous,Leukemias, Ph1-Positive Myeloid,Leukemias, Philadelphia-Positive Myeloid,Myelocytic Leukemias, Chronic,Myelogenous Leukemia, Ph1 Positive,Myelogenous Leukemias, Chronic,Myelogenous Leukemias, Ph1-Positive,Myeloid Leukemia, Ph1 Positive,Myeloid Leukemia, Philadelphia Positive,Myeloid Leukemias, Chronic,Myeloid Leukemias, Ph1-Positive,Myeloid Leukemias, Philadelphia-Positive,Ph1-Positive Myelogenous Leukemia,Ph1-Positive Myelogenous Leukemias,Ph1-Positive Myeloid Leukemia,Ph1-Positive Myeloid Leukemias,Philadelphia-Positive Myeloid Leukemia,Philadelphia-Positive Myeloid Leukemias
D042381 Granulocyte Precursor Cells The cells in the granulocytic series that give rise to mature granulocytes (NEUTROPHILS; EOSINOPHILS; and BASOPHILS). These precursor cells include myeloblasts, promyelocytes, myelocytes and metamyelocytes. Myeloblasts,Promyelocytes,Granulocyte Progenitor Cells,Granulocyte Progenitors,Granulocytic Precursor Cells,Metamyelocytes,Myeloblast,Myelocytes,Premyelocytes,Progranulocytes,Cell, Granulocyte Precursor,Cell, Granulocyte Progenitor,Cell, Granulocytic Precursor,Cells, Granulocyte Precursor,Cells, Granulocyte Progenitor,Cells, Granulocytic Precursor,Granulocyte Precursor Cell,Granulocyte Progenitor,Granulocyte Progenitor Cell,Granulocytic Precursor Cell,Metamyelocyte,Myelocyte,Precursor Cell, Granulocyte,Precursor Cell, Granulocytic,Precursor Cells, Granulocyte,Precursor Cells, Granulocytic,Premyelocyte,Progenitor Cell, Granulocyte,Progenitor Cells, Granulocyte,Progenitor, Granulocyte,Progenitors, Granulocyte,Progranulocyte,Promyelocyte
D047428 Protein Kinase Inhibitors Agents that inhibit PROTEIN KINASES. Protein Kinase Inhibitor,Inhibitor, Protein Kinase,Inhibitors, Protein Kinase,Kinase Inhibitor, Protein,Kinase Inhibitors, Protein

Related Publications

Federico Angriman, and Maria Nelly Gutierrez Acevedo, and Maria Sol Rossi, and Alberto Daniel Gimenez Conca, and Victoria Otero, and Jorge Alberto Arbelbide, and Hernán Michelángelo
Promyelocytic blast crisis of chronic myeloid leukemia during imatinib treatment.
January 2008, Annals of clinical and laboratory science,
Federico Angriman, and Maria Nelly Gutierrez Acevedo, and Maria Sol Rossi, and Alberto Daniel Gimenez Conca, and Victoria Otero, and Jorge Alberto Arbelbide, and Hernán Michelángelo
Promyelocytic blast crisis of chronic myelogenous leukemia during imatinib treatment.
January 2007, Acta haematologica,
Federico Angriman, and Maria Nelly Gutierrez Acevedo, and Maria Sol Rossi, and Alberto Daniel Gimenez Conca, and Victoria Otero, and Jorge Alberto Arbelbide, and Hernán Michelángelo
t(15;17) in a promyelocytic form of chronic myeloid leukemia blastic crisis.
February 1983, Cancer genetics and cytogenetics,
Federico Angriman, and Maria Nelly Gutierrez Acevedo, and Maria Sol Rossi, and Alberto Daniel Gimenez Conca, and Victoria Otero, and Jorge Alberto Arbelbide, and Hernán Michelángelo
Sudden blastic crisis and additional chromosomal abnormalities during chronic myeloid leukemia in the imatinib era.
December 2009, International journal of clinical oncology,
Federico Angriman, and Maria Nelly Gutierrez Acevedo, and Maria Sol Rossi, and Alberto Daniel Gimenez Conca, and Victoria Otero, and Jorge Alberto Arbelbide, and Hernán Michelángelo
[Blastic crisis of chronic myeloid leukemia].
October 1978, Orvosi hetilap,
Federico Angriman, and Maria Nelly Gutierrez Acevedo, and Maria Sol Rossi, and Alberto Daniel Gimenez Conca, and Victoria Otero, and Jorge Alberto Arbelbide, and Hernán Michelángelo
[Blastic crisis in chronic myeloid leukemia: megakaryoblastic leukemia?].
September 1976, L'union medicale du Canada,
Federico Angriman, and Maria Nelly Gutierrez Acevedo, and Maria Sol Rossi, and Alberto Daniel Gimenez Conca, and Victoria Otero, and Jorge Alberto Arbelbide, and Hernán Michelángelo
Treatment of myeloid blastic crisis of chronic myelogenous leukemia.
November 1984, Cancer treatment reports,
Federico Angriman, and Maria Nelly Gutierrez Acevedo, and Maria Sol Rossi, and Alberto Daniel Gimenez Conca, and Victoria Otero, and Jorge Alberto Arbelbide, and Hernán Michelángelo
Safety of imatinib in chronic myeloid leukemia in blastic crisis presenting as cholestatic jaundice.
January 2007, Acta haematologica,
Federico Angriman, and Maria Nelly Gutierrez Acevedo, and Maria Sol Rossi, and Alberto Daniel Gimenez Conca, and Victoria Otero, and Jorge Alberto Arbelbide, and Hernán Michelángelo
Spontaneous leukocyte oscillation during blastic crisis of chronic myeloid leukemia.
June 1974, Cancer,
Federico Angriman, and Maria Nelly Gutierrez Acevedo, and Maria Sol Rossi, and Alberto Daniel Gimenez Conca, and Victoria Otero, and Jorge Alberto Arbelbide, and Hernán Michelángelo
Promyelocytic crisis of chronic myelogenous leukaemia during imatinib mesylate treatment.
January 2007, Acta haematologica,
Copied contents to your clipboard!